<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084890</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000366942</org_study_id>
    <secondary_id>CCCWFU-30102B</secondary_id>
    <secondary_id>NCI-6949</secondary_id>
    <nct_id>NCT00084890</nct_id>
  </id_info>
  <brief_title>Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix</brief_title>
  <official_title>Weekly Docetaxel and Carboplatin in Patients With Recurrent Squamous Carcinoma of the Cervix: A Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Combining docetaxel with&#xD;
      carboplatin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of docetaxel when&#xD;
      given together with carboplatin and to see how well they work in treating patients with&#xD;
      recurrent stage IVB squamous cell carcinoma (cancer) of the cervix.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of docetaxel when administered with carboplatin in&#xD;
           patients with recurrent stage IVB squamous cell carcinoma of the cervix.&#xD;
&#xD;
        -  Determine the response rate and time to progression in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is phase I, dose-escalation study of docetaxel followed by a phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive docetaxel IV over 30 minutes and carboplatin IV over 30&#xD;
           minutes on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in&#xD;
           the absence of disease progression or unacceptable toxicity. Patients who demonstrate&#xD;
           continuing tumor shrinkage after 6 courses receive 2 additional courses beyond their&#xD;
           best response.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of docetaxel until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive docetaxel and carboplatin as in phase I at the MTD determined&#xD;
           in phase I.&#xD;
&#xD;
      Quality of life is assessed at baseline, before every other course of treatment, and at the&#xD;
      end of study treatment.&#xD;
&#xD;
      Patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-64 patients (3-24 for phase I and 16-40 for phase II) will be&#xD;
      accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of docetaxel</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>30 minute infusion dosed based on glomerular filtration rate of patient</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>escalating doses ofstarting at 25 milligrams per meter squared</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the uterine cervix&#xD;
&#xD;
               -  Advanced disease (stage IVB)&#xD;
&#xD;
               -  Persistent or recurrent disease&#xD;
&#xD;
          -  No available curative treatment options&#xD;
&#xD;
          -  Measurable disease by physical examination, chest x-ray, CT scan, or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  GOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 8 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN) AND alkaline phosphatase normal&#xD;
             OR&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 4 times ULN AND SGOT and SGPT normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other invasive malignancy within the past 5 years&#xD;
&#xD;
          -  No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with&#xD;
             polysorbate 80&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No other concurrent malignancy except curatively treated non-melanoma skin cancer&#xD;
&#xD;
          -  No other serious medical or psychiatric illness that would preclude giving informed&#xD;
             consent or limit survival&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens&#xD;
&#xD;
               -  One sensitizing chemotherapy regimen during radiotherapy AND 1 regimen for&#xD;
                  recurrent disease are considered 2 regimens&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No prior docetaxel&#xD;
&#xD;
          -  No prior carboplatin&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 4 weeks since prior hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte E. Miller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>cervical squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

